Back to Directory
SynaptixBio
Founded 2021
Antisense oligonucleotide therapies for TUBB4A-associated leukodystrophies
SynaptixBio is a biotechnology company developing antisense oligonucleotide therapies for severe inherited leukodystrophies.
Its lead programme targets TUBB4A-associated hypomyelinating disorders, including hypomyelination with atrophy of the basal ganglia and cerebellum (H-ABC). The approach uses synthetic oligonucleotides to suppress disease-associated TUBB4A expression.
The company has selected a development candidate and holds US orphan drug designations for relevant TUBB4A disorders. Its lead therapy remains in development ahead of clinical testing.